Frequently Asked
Questions.

Florya is a clinical screening platform for women's health that correlates symptoms, lifestyle factors, and lab biomarkers to generate physician-ready evidence reports for conditions like PCOS, Endometriosis, Hormonal Health disorders, and Metabolic & Thyroid dysfunction.

Yes. Florya's screening assessments are completely free, and we intend to keep them that way. There are no hidden fees, no premium tiers, and no paywalls. Our mission is to close the diagnostic gap in women's health — cost should never be a barrier to clinical clarity. Note that if your assessment recommends lab tests, those are obtained through your doctor or a lab provider and may carry their own costs independent of Florya.

Florya is currently available in India. Our screening assessments, clinical protocols, and physician-ready reports are designed for the Indian healthcare context. We plan to expand to additional regions in the future.

No. Florya is a clinical screening and decision-support tool, not a medical device. Our assessments generate structured evidence summaries that your healthcare provider can use to guide diagnosis and treatment. Florya does not provide medical diagnoses.

Yes. Florya uses end-to-end encryption for all health data. We do not sell or share personal health information with third parties. Your data is stored securely and you maintain full control over who can access your reports.

The initial symptom assessment takes under 10 minutes to complete. If you have lab results to upload, the full process including biomarker analysis takes approximately 15-20 minutes.

No referral is needed. Florya is designed to be accessible directly. However, we recommend sharing your clinical report with your healthcare provider for follow-up care and any further diagnostic investigation.

Yes. Every Florya report is designed to be physician-ready. You can download, print, or share your structured clinical evidence summary directly with your healthcare provider to support your consultation.

Your screening results are generated instantly after you complete the assessment. If you upload lab results, the biomarker analysis is also processed immediately. There is no waiting period — your physician-ready report is available as soon as you finish.

Yes. You can retake the Florya assessment at any time. If your symptoms change, you receive new lab results, or you simply want to reassess, you can start a fresh screening. Your previous reports are saved so you can track how your health picture evolves.

Share your report with your healthcare provider. The report includes structured risk scoring, clinical indicators, and a recommended care path — all in terminology your doctor will recognize. Use it to have a more informed conversation about next steps, whether that means additional testing, imaging, or specialist referral.

That's a valid outcome. Not every symptom pattern points to PCOS, Endometriosis, or the other conditions Florya screens for. If your risk scores are low across all conditions, your report will reflect that — and you can share it with your doctor for peace of mind or to explore other possibilities.

Yes. Florya is designed specifically for women's health conditions — PCOS, Endometriosis, hormonal health disorders, and metabolic & thyroid conditions as they present in women. While some conditions like thyroid dysfunction affect all genders, our screening protocols and clinical frameworks are calibrated for the female presentation.

Florya uses the Rotterdam Protocol — the international diagnostic standard — to assess three key criteria: hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology indicators. Our questionnaire captures symptom patterns while lab results provide biomarker confirmation.

Our assessment classifies PCOS into four phenotypes (Types A-D) based on which Rotterdam criteria are present. Type A (Classic) shows all three criteria, while Type D shows only polycystic morphology and ovulatory dysfunction. This classification helps your physician tailor treatment.

Florya provides clinical screening, not a medical diagnosis. Our assessment generates a risk score and evidence summary that your healthcare provider can use to guide further investigation and formal diagnosis.

Based on your symptom profile, Florya may recommend testing AMH, LH, FSH, Total and Free Testosterone, DHEA-S, SHBG, and Fasting Insulin. These markers help confirm hyperandrogenism and metabolic involvement.

PCOS is classified into four phenotypes using the Rotterdam criteria: Type A (Classic/Full) presents with all three criteria — hyperandrogenism, ovulatory dysfunction, and polycystic morphology. Type B shows hyperandrogenism and ovulatory dysfunction without polycystic morphology. Type C presents with hyperandrogenism and polycystic morphology but regular ovulation. Type D shows ovulatory dysfunction and polycystic morphology without hyperandrogenism.

Yes. PCOS is an endocrine (hormonal) disorder characterized by excess androgens (male hormones), irregular ovulation, and metabolic dysfunction. It often involves insulin resistance, which drives further hormonal imbalance. Treatment approaches address both the hormonal and metabolic components.

Clinical screening using the Rotterdam Protocol can identify PCOS risk through symptom assessment and biomarker analysis (AMH, LH/FSH ratio, testosterone, insulin) without requiring ultrasound. While ultrasound confirms polycystic ovarian morphology, two of the three Rotterdam criteria can be assessed through clinical and biochemical evaluation alone.

Florya assesses pelvic pain patterns, menstrual symptoms, and inflammatory markers using criteria aligned with ASRM (American Society for Reproductive Medicine) guidelines. While laparoscopy is the gold standard for diagnosis, our screening identifies risk indicators that warrant further investigation.

Florya screens for fibroid risk factors by analyzing symptoms like heavy menstrual bleeding, pelvic pressure, and pain patterns. Our assessment can identify patterns that suggest fibroids and recommend appropriate imaging (pelvic/transvaginal ultrasound).

Screening identifies risk indicators and symptom patterns suggestive of endometriosis. Formal diagnosis typically requires imaging or surgical confirmation. Florya provides the structured evidence your doctor needs to justify further investigation.

While laparoscopy remains the gold standard for definitive diagnosis, non-invasive approaches are improving. Symptom-based screening tools, transvaginal ultrasound, MRI, and biomarkers like CA-125 can identify endometriosis risk indicators without surgery. Florya combines symptom pattern analysis with biomarker correlation to provide a non-invasive risk assessment.

CA-125 is the most commonly studied blood marker for endometriosis, though it is not definitive on its own. Elevated CRP and ESR (inflammatory markers) may also indicate the chronic inflammation associated with endometriosis. Florya correlates these markers with your symptom profile for a more comprehensive assessment.

Endometriosis occurs when tissue similar to the uterine lining grows outside the uterus, causing inflammation and pain. Uterine fibroids are non-cancerous growths within the uterine wall that can cause heavy bleeding and pelvic pressure. Both conditions can coexist and share symptoms like pelvic pain, which is why Florya screens for both simultaneously.

POI occurs when the ovaries stop functioning normally before age 40, leading to reduced estrogen production and irregular or absent periods. Early detection through biomarker screening (FSH, AMH, Estradiol) is crucial for fertility planning and bone health.

HA is caused by hypothalamic suppression (often from stress, low body weight, or excessive exercise), while PCOS involves excess androgens and metabolic dysfunction. Both can cause missed periods, but treatment approaches are different. Florya helps distinguish between the two.

Any woman experiencing irregular or absent periods, unexplained mood changes, hot flashes, or signs of premature aging should consider hormonal screening. It is especially important for women planning future pregnancies.

Early signs of Premature Ovarian Insufficiency include irregular or missed periods, hot flashes, night sweats, vaginal dryness, difficulty concentrating, and decreased fertility. These symptoms can appear gradually or suddenly. Early detection through FSH, AMH, and Estradiol testing allows for timely intervention to protect bone health and fertility.

Yes, Hypothalamic Amenorrhea (HA) is often reversible. The primary approach involves addressing the underlying cause — reducing excessive exercise, improving caloric intake, managing stress, and achieving a healthy body weight. Recovery of menstrual cycles typically follows within 3-6 months of sustained lifestyle changes, though individual timelines vary.

HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) measures how effectively your body uses insulin. Elevated HOMA-IR is a key marker in PCOS, pre-diabetes, and metabolic syndrome. Standard labs often report insulin as "normal" while HOMA-IR reveals functional resistance.

TSH alone misses many thyroid issues. Free T3, Free T4, and TPO antibodies reveal the full picture — including subclinical hypothyroidism, Hashimoto’s antibody patterns, and conversion problems that TSH alone cannot detect.

Insulin resistance drives androgen overproduction in PCOS, while thyroid dysfunction can worsen metabolic symptoms. Florya screens both together because treating one without addressing the other often leads to incomplete improvement.

A HOMA-IR score below 1.0 is generally considered optimal. Scores between 1.0-2.0 suggest early insulin resistance, while scores above 2.0 indicate significant insulin resistance. However, standard lab reports often only flag fasting insulin or glucose without calculating HOMA-IR, which can miss early metabolic dysfunction.

TSH is a pituitary hormone that signals the thyroid, but it does not reflect the complete thyroid picture. Free T3 and Free T4 measure actual thyroid hormone levels, while TPO antibodies detect autoimmune thyroid conditions like Hashimoto's. A "normal" TSH can coexist with subclinical hypothyroidism, poor T4-to-T3 conversion, or early Hashimoto's — all of which require the full panel to detect.